financetom
GCMG
financetom
/
Financials
/
GCMG
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
GCM Grosvenor IncGCMG
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Grosvenor Capital Management, L.P. is global alternative asset management solutions provider.

The firm primarily provides its services to pooled investment vehicles. It also provides its services to investment companies, high net worth individuals, pension and profit sharing plans and state or municipal government entities.

The firm invests in equity and alternative investment markets of the United States and internationally.

The firm invests in multi-strategy, credit-focused, equity-focused, macro-focused, commodity-focused, and other specialty portfolios.

It focuses in hedge fund asset classes, private equity, real estate, and/or infrastructure, credit and absolute return strategies.

It also focuses in primary fund investments, secondary fund investments, and co-investments with a focus on buyout, distressed debt, mezzanine, venture capital/growth equity investments.

The firm seeks to do seed investments in small, emerging, and diverse private equity firms. The firm seeks to make regionally-focused investments in middle-market buyout.

It prefers to invest in aerospace and defense, advanced electronics, information technology, biosciences, and advanced materials.

It focuses on Ohio and the Midwest region. The firm employs fundamental and quantitative analysis.

Grosvenor Capital Management, L.P. was founded in 1971 and is based in Chicago, Illinois with additional offices in North America, Asia, Australia and Europe.

Latest News >
Sanofi Says European Union Approves Drug to Delay Onset of Stage 3 Type 1 Diabetes
Sanofi Says European Union Approves Drug to Delay Onset of Stage 3 Type 1 Diabetes
Nov 14, 2025
07:04 AM EST, 11/14/2025 (MT Newswires) -- Sanofi ( SNY ) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of the therapy Teizeild for delaying the onset of stage 3 type 1 diabetes in adult and pediatric patients eight years of age and older with stage 2 type 1 diabetes. The opinion...
BRIEF-Legence Announces Agreement To Acquire Bowers
BRIEF-Legence Announces Agreement To Acquire Bowers
Nov 14, 2025
Nov 14 (Reuters) - Legence Corp ( LGN ): * LEGENCE ANNOUNCES AGREEMENT TO ACQUIRE BOWERS * LEGENCE ANNOUNCES AGREEMENT TO ACQUIRE BOWERS * LEGENCE CORP ( LGN ): ACQUISITION CONSIDERATION IS APPROXIMATELY $475 MILLION * LEGENCE CORP ( LGN ): BOWERS IS EXPECTED TO ADD SIGNIFICANT REVENUE, EBITDA AND BACKLOG TO LEGENCE * LEGENCE ( LGN ): CASH PORTION...
Merck Agrees to Acquire Cidara Therapeutics for $9.2 Billion
Merck Agrees to Acquire Cidara Therapeutics for $9.2 Billion
Nov 14, 2025
07:04 AM EST, 11/14/2025 (MT Newswires) -- Merck ( MRK ) said Friday it has agreed for a subsidiary to acquire all outstanding shares of Cidara Therapeutics ( CDTX ) for $221.50 per share in cash, valuing the transaction at about $9.2 billion. The company said the transaction has been approved by the boards of both companies. The acquisition is...
Swiss Capital S.A. Acquires Units of Gabriel Resources Ltd. In Private Placement
Swiss Capital S.A. Acquires Units of Gabriel Resources Ltd. In Private Placement
Nov 14, 2025
This press release is issued pursuant to Multilateral Instrument 62-104 - Take-Over Bids and Issuer Bids and National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues. BUCHAREST, RO / ACCESS Newswire / November 14, 2025 / On November 12, 2025, Swiss Capital S.A. (Swiss Capital) acquired 10,781,571 units (Units) of Gabriel Resources Ltd....
Copyright 2023-2026 - www.financetom.com All Rights Reserved